China vs Timor-Leste: Average cost of multi drug-resistant tuberculosis treatment
China
20,028 constant 2022 US$
in 2024
Timor-Leste
50,471 constant 2022 US$
in 2024
China rank
4th
Timor-Leste rank
2nd
Average cost of multi drug-resistant tuberculosis treatment over time
- China
- Timor-Leste
How they compare
Timor-Leste currently reports 50,471 constant 2022 US$ against 20,028 constant 2022 US$ in China, a difference of 30,443 constant 2022 US$.
That makes Timor-Leste's figure about 2.5 times China's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was China ahead.
China ranks 4th and Timor-Leste ranks 2nd of 92 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Timor-Leste | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 6,001 constant 2022 US$ | 1,816 constant 2022 US$ | 4,185 constant 2022 US$ | China |
| 2020s | 20,415 constant 2022 US$ | 10,485 constant 2022 US$ | 9,930 constant 2022 US$ | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, China or Timor-Leste?
- Timor-Leste, at 50,471 constant 2022 US$ against 20,028 constant 2022 US$ in China as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between China and Timor-Leste?
- 30,443 constant 2022 US$, with Timor-Leste ahead.
- How many years of comparable data are there for China and Timor-Leste?
- 8 years are reported by both, from 2017 to 2024.
- How do China and Timor-Leste rank globally for average cost of multi drug-resistant tuberculosis treatment?
- China ranks 4th and Timor-Leste ranks 2nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.